Systematic review and Meta analysis of efficacy and safety of subcutaneous bortezomib in the treatment for multiple myeloma
10.13699/j.cnki.1001-6821.2017.09.020
- VernacularTitle:皮下硼替佐米治疗多发性骨髓瘤疗效和安全性的系统评价和Meta分析
- Author:
Yun ZHUANG
1
;
Zhi-Chao JIN
;
Ou JI
;
Qun SHEN
Author Information
1. 南京中医药大学第一附属医院、江苏省中医院血液科
- Keywords:
multiple myeloma;
subcutaneous;
intravenous;
bortezomib;
peripheral neuropathy;
Meta analysis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(9):841-844
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically assess the effectiveness and safety of subcutaneous bortezomibin comparison with intravenous bortezomib for treating multiple myeloma.Methods Data from relative clinical trials were from Clinicaltrials.gov and Cochrane Collaboration.A comprehensive literature search was performed from data bases such as PubMed and EmBase.The data of effective and safety on subcutaneous and intravenous administration was comparison.The Meta analyzed by RevMan5.3 Software.Results Three randomized controlled trials (RCT) and 8 retrospective cohort studies(RCS),11 research papers in total met inclusion criteria,including 2021 cases.There were no significant differences between the subcutaneous bortezomib group and the intravenous bortezomib group in the overall responses rate [OR =1.06,95％ CI (0.84,1.33)] and complete response [OR =0.93,95％ CI (0.65,1.31)].In terms of safety,the incidence of peripheral neuropathy and grade ≥3 peripheral neuropathy were significantly lower in subcutaneous bortezomib group than those in intravenous bortezomib group with siginificance [OR =0.44,95％ CI (0.35,0.56);OR =0.30,95％ CI (0.19,0.46),respectively] (P ＜ 0.001).Conclusion Subcutaneous bortezomib is as effective as intravenous bortezomib in multiple myeloma and reduce the incidence of peripheral neuropathy.
